|
Q4 2021
Filed on Feb 11, 2022
|
10,902
|
N/A
|
|
|
Q4 2021
Filed on Feb 11, 2022
|
34,538
|
$1.18 - $1.74
$40.8K - $60.1K
|
|
|
Q4 2021
Filed on Feb 11, 2022
|
21,443
|
N/A
|
|
|
Q4 2021
Filed on Feb 11, 2022
|
14,139
|
N/A
|
|
|
Q4 2021
Filed on Feb 11, 2022
|
22,429
|
$1.33 - $2.77
$29.8K - $62.1K
|
|
Calithera Biosciences Inc
|
Q4 2021
Filed on Feb 11, 2022
|
18,340
|
N/A
|
|
Pennsylvania Real Estate Inv
|
Q4 2021
Filed on Feb 11, 2022
|
13,968
|
N/A
|
|
|
Q4 2021
Filed on Feb 11, 2022
|
5,292
|
$42.83 - $53.49
$227K - $283K
|
|
|
Q4 2021
Filed on Feb 11, 2022
|
10,383
|
$1.56 - $2.99
$16.2K - $31K
|
|
|
Q4 2021
Filed on Feb 11, 2022
|
26,951
|
$1.64 - $3.13
$44.2K - $84.4K
|
|
|
Q4 2021
Filed on Feb 11, 2022
|
18,670
|
N/A
|
|
|
Q4 2021
Filed on Feb 11, 2022
|
11,908
|
N/A
|
|
|
Q4 2021
Filed on Feb 11, 2022
|
14,723
|
$10.86 - $12.69
$160K - $187K
|
|
|
Q4 2021
Filed on Feb 11, 2022
|
13,289
|
$2.27 - $3.0
$30.2K - $39.9K
|
|
|
Q4 2021
Filed on Feb 11, 2022
|
20,736
|
$3.76 - $7.99
$78K - $166K
|
|
|
Q4 2021
Filed on Feb 11, 2022
|
5,313
|
$38.64 - $45.04
$205K - $239K
|
|
|
Q4 2021
Filed on Feb 11, 2022
|
57,573
|
$1.24 - $2.31
$71.4K - $133K
|
|
|
Q4 2021
Filed on Feb 11, 2022
|
773
|
$630.6 - $703.62
$487K - $544K
|
|
|
Q4 2021
Filed on Feb 11, 2022
|
18,002
|
$1.88 - $2.9
$33.8K - $52.2K
|
|
|
Q4 2021
Filed on Feb 11, 2022
|
25,319
|
N/A
|
|
New Oriental Ed & Technology
|
Q4 2021
Filed on Feb 11, 2022
|
95,248
|
N/A
|
|
|
Q4 2021
Filed on Feb 11, 2022
|
9,110
|
$28.4 - $48.53
$259K - $442K
|
|
|
Q4 2021
Filed on Feb 11, 2022
|
30,847
|
$1.0 - $2.0
$30.8K - $61.7K
|
|
|
Q4 2021
Filed on Feb 11, 2022
|
17,217
|
$1.33 - $2.84
$22.9K - $48.9K
|
|
Dicerna Pharmaceuticals Inc
|
Q4 2021
Filed on Feb 11, 2022
|
17,008
|
N/A
|
|
|
Q4 2021
Filed on Feb 11, 2022
|
23,516
|
N/A
|
|
|
Q4 2021
Filed on Feb 11, 2022
|
15,882
|
$0.58 - $1.09
$9.21K - $17.3K
|
|
|
Q4 2021
Filed on Feb 11, 2022
|
41,324
|
N/A
|
|
Eyegate Pharmaceuticals Inc
|
Q4 2021
Filed on Feb 11, 2022
|
13,867
|
N/A
|
|
|
Q4 2021
Filed on Feb 11, 2022
|
1,862
|
N/A
|
|
|
Q4 2021
Filed on Feb 11, 2022
|
5,143
|
$45.08 - $55.96
$232K - $288K
|
|
|
Q4 2021
Filed on Feb 11, 2022
|
19,990
|
$0.01 - $0.19
$200 - $3.8K
|
|
|
Q4 2021
Filed on Feb 11, 2022
|
4,420
|
N/A
|
|
Investors Bancorp Inc New
|
Q4 2021
Filed on Feb 11, 2022
|
18,680
|
N/A
|
|
|
Q4 2021
Filed on Feb 11, 2022
|
2,223
|
N/A
|
|
|
Q4 2021
Filed on Feb 11, 2022
|
13,883
|
N/A
|
|
|
Q4 2021
Filed on Feb 11, 2022
|
4,067
|
N/A
|
|
|
Q4 2021
Filed on Feb 11, 2022
|
18,114
|
$8.3 - $12.0
$150K - $217K
|
|
Enable Midstream Partners LP
|
Q3 2021
Filed on Nov 12, 2021
|
15,343
|
N/A
|
|
Washington Prime Group New
|
Q3 2021
Filed on Nov 12, 2021
|
11,898
|
N/A
|
|
|
Q3 2021
Filed on Nov 12, 2021
|
14,469
|
$23.11 - $25.02
$334K - $362K
|
|
|
Q3 2021
Filed on Nov 12, 2021
|
4,351
|
$146.49 - $189.88
$637K - $826K
|
|
|
Q3 2021
Filed on Nov 12, 2021
|
16,993
|
N/A
|
|
|
Q3 2021
Filed on Nov 12, 2021
|
10,587
|
$8.85 - $9.91
$93.7K - $105K
|
|
Aerpio Pharmaceuticals Inc
|
Q3 2021
Filed on Nov 12, 2021
|
17,331
|
N/A
|
|
Adamas Pharmaceuticals Inc
|
Q3 2021
Filed on Nov 12, 2021
|
16,357
|
N/A
|
|
|
Q3 2021
Filed on Nov 12, 2021
|
12,444
|
$20.03 - $22.59
$249K - $281K
|
|
|
Q3 2021
Filed on Nov 12, 2021
|
76,941
|
N/A
|
|
|
Q3 2021
Filed on Nov 12, 2021
|
10,846
|
$2.77 - $3.74
$30K - $40.6K
|
|
|
Q3 2021
Filed on Nov 12, 2021
|
14,901
|
$0.88 - $1.22
$13.1K - $18.2K
|
|